“A new clinical trial is drawing attention to the potential of psilocybin... Researchers followed people with cancer who were experiencing depression after receiving a single supervised dose of psilocybin alongside psychotherapy. Nearly 50% remained in remission from depression about two years later, suggesting that the benefits may last…”
Plain restatementA published clinical trial reported that approximately half of cancer patients with major depressive disorder who received one supervised 25 mg dose of psilocybin combined with psychological support were in depression remission at a two-year follow-up assessment.
This post is largely accurate. There is a real peer reviewed trial, published in the journal Cancer in June 2025, in which 30 cancer patients with major depression received one supervised 25 mg dose of psilocybin alongside individual and group therapy. At the two year follow up, 14 of the 28 remaining patients, or 50 percent, met the study's definition of sustained improvement and remission. The post is also responsible in stating that this does not mean mushrooms cure depression. However, it leaves out important context. The study had no placebo or control group, which means the improvement cannot be firmly attributed to psilocybin itself, and the sample was very small and from a single site. Most importantly, the paper reports that only 7 of the 28 patients, about 25 percent, kept the benefit without taking antidepressants or a second psychedelic treatment during the follow up period, so the clean "one dose lasted two years" picture applies to fewer people than the post implies. The results are also not new, and a randomized placebo controlled trial testing this properly is still underway.
A [drifted from the evidence:] new clinical trial [drifted from the evidence:] is drawing attention to the potential of [drifted from the evidence:] psilocybin... Researchers followed people with cancer who [drifted from the evidence:] were experiencing depression after receiving a single supervised dose of psilocybin [drifted from the evidence:] alongside psychotherapy. Nearly 50% remained in [drifted from the evidence:] remission from depression [drifted from the evidence:] about two years later, suggesting that the benefits may last much longer than expected in some patients.
A [added by the neutral restatement:] published clinical trial [added by the neutral restatement:] reported that approximately half of cancer [added by the neutral restatement:] patients with major depressive disorder who [added by the neutral restatement:] received one supervised [added by the neutral restatement:] 25 mg dose of psilocybin [added by the neutral restatement:] combined with psychological support were in depression [added by the neutral restatement:] remission at a two-year follow-up assessment.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The trial exists, is peer reviewed, and was published in Cancer, a journal of the American Cancer Society.
- The population is correctly described: people with cancer who had major depressive disorder.
- The intervention is correctly described: a single supervised dose of psilocybin combined with psychotherapy, in a controlled medical setting.
- The 50% remission-at-two-years figure is accurate and matches the primary source. "Nearly 50%" slightly understates it; it was exactly 14 of 28, or 50%.
- The post's cautions are accurate and unusually responsible: it explicitly says this does not mean mushrooms cure depression, notes the controlled setting, notes risks, and notes legal status.
- A randomized, double-blind trial is currently evaluating up to two doses of 25 mg psilocybin versus placebo for depression and anxiety in patients with cancer , so the post's statement that research continues is correct.
- Omitted qualifier (most significant): The post attributes two-year remission to "a single supervised dose." The paper reports that only 7 of 28 patients (25%) sustained the benefit at 24 months without any additional antidepressant or psychedelic treatment. The other half of the 50% group received antidepressants after psilocybin, and three received a second psychedelic treatment. The clean "one dose, two years" framing therefore applies to roughly a quarter of participants, not half.
- Omitted qualifier: No control group and open-label design. Every participant knew they received psilocybin. Improvement cannot be causally separated from placebo response, natural course of depression, cancer treatment outcomes, or the substantial therapy component.
- Omitted qualifier: Very small sample. Thirty enrolled, 28 analyzed, single site. One or two patients shift the percentage by several points.
- Temporal framing: "A new clinical trial" is inaccurate as of the post date. The two-year results were published in June 2025, and the dosing itself occurred in 2020 and 2021.
- Population mismatch in the closing line: the post ends by framing this as hope for "treatment-resistant depression," but participants in this trial were required to not be taking antidepressants at screening and were not characterized as treatment resistant. This is a different population from the treatment-resistant depression trials.
- Omitted context: partial industry funding by Compass Pathways and author ties to the sponsor.
- Survivorship: two participants died before the 24-month assessment and were excluded from the denominator.
- Whether the post is referring to this specific 2025 paper cannot be confirmed from the post itself, because it cites no source, no journal, no author, and no date. The numbers and description match the Agrawal et al. Cancer paper closely enough that no other candidate study was found, but the attribution is inferred, not stated.
- Whether "remission" in the post means the paper's MADRS ≤ 10 definition. The post does not define it. The match is presumed.
- Long-term outcomes beyond 24 months for this cohort were not found.
- Whether the ongoing randomized placebo-controlled follow-on trial will replicate these results is unknown. Results were not located.
The underlying study is real and the headline number is accurate. A phase 2 trial tested a single dose of psilocybin combined with psychological support in a community cancer setting in 30 patients with cancer and major depressive disorder, and the paper reports efficacy outcomes at two years' follow-up. Of 28 patients, 15 (53.6%) demonstrated significant reduction in depression as measured by the Montgomery Asberg Depression Rating Scale (average −15.0 points from baseline; p < .001), and 14 (50%) had sustained depression reduction. Thirteen patients (46.4%) experienced significant reduction in anxiety on the Hamilton Anxiety Rating Scale (average −13.9 points from baseline, p < .001), and 12 (42.9%) had sustained anxiety reduction. The single most important detail omitted from the viral post appears in the paper itself: twenty-five percent (seven patients) experienced sustained reduction in depression at 24 months from a single psilocybin dose without any additional psychedelic or antidepressant treatments; among the others, 25% (seven) received antidepressants after psilocybin and three of those received a second psychedelic treatment.
Complete reasoning
The reply receipt is formatted for pasting into the thread where the claim is circulating.
Compact share page: verify.trueseeker.com/s/089d58e158a3/EvU37aAVBA8yb2EQWbhrkp3
Ask this case
Answers come only from the case file above; nothing is added.
Is it true that half of the patients stayed in remission for two years after just one dose?
Half is accurate for the overall remission figure, but only about 25 percent of patients kept the benefit from the single dose alone. The other half of that group received antidepressants afterward, and some received a second psychedelic treatment.
Did this study have a placebo or control group?
No. The trial was open label with no control group, meaning every participant knew they had received psilocybin. This makes it impossible to firmly separate the drug's effect from placebo response or other factors.
How many people were in this study?
Thirty people enrolled and 28 were included in the two-year follow-up analysis, at a single site. This is a small sample, so a shift of one or two patients changes the percentages noticeably.
Is this a brand new trial?
No. The two-year results were published in June 2025, but the dosing itself took place in 2020 and 2021. Describing it as a new trial is not accurate.
Does this mean psilocybin works for treatment-resistant depression?
The case file does not support that. Participants in this trial were not on antidepressants at screening and were not described as having treatment-resistant depression, so this is a different population than treatment-resistant depression studies.